Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director's Dealings

7 Mar 2017 17:27

RNS Number : 7952Y
Premier Veterinary Group PLC
07 March 2017
 

 

 

 

PREMIER VETERINARY GROUP PLC

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

 

 

 

London, UK, 7 March 2017 (LSE: PVG): Premier Veterinary Group plc (the "Company") announces that on 3 March 2017 it granted 40,000 options over its ordinary shares of 10 pence each to Will Evans, Chief Financial Officer and a Director of the Company, under the Company's Enterprise Management Incentive Share Option Plan, with an exercise price of 238.75 pence per share. Following this grant, Will Evans holds 40,000 options.

 

The options will become exercisable on the third anniversary of the date of grant and remain exercisable up to and including the tenth anniversary of the date of grant, to the extent that the performance targets applicable to the options have been met. As disclosed in the Company's annual report and accounts for the year ended 30 September 2016, the performance targets are based on the growth in the number of pets on the Company's preventative healthcare programme for pets (Premier Pet Care Plan) to a pre-determined level, and the Company's share price increasing to at least twice the share price at the date of grant.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

WILLIAM EDWARD FRANK EVANS

2

Reason for the notification

 

a)

Position/status

 

Chief Financial Officer/Executive Director

b)

Initial notification/ Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Premier Veterinary Group plc

 

b)

LEI

 2138009B5L8VQUZ9A719

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of £0.10 each

 

 

 

ISIN: GB00BSZLMS59

b)

Nature of the transaction

Grant of options to acquire shares

 

c)

Price(s) and volume(s)

40,000 options to acquire ordinary shares at an exercise price of 238.75 pence per share 

d)

Aggregated information

 

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

3 March 2017

 

f)

Place of the transaction

Outside a trading venue

 

 

For further information, please contact:

 

Premier Veterinary Group plc Tel:  +44(0)117 970 4127

 

Dominic Tonner, Chief Executive Officer

Will Evans, Chief Financial Officer

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHZMGGFNNVGNZM
Date   Source Headline
10th Mar 20101:21 pmRNSEPT Disclosure
10th Mar 201011:52 amRNSEPT Disclosure
10th Mar 20107:00 amRNSFinal Results
9th Mar 20107:00 amRNSResearch Update
8th Mar 20105:34 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSResearch Update
19th Feb 20107:00 amRNSRe Agreement
16th Feb 20104:40 pmRNSSecond Price Monitoring Extn
16th Feb 20104:35 pmRNSPrice Monitoring Extension
11th Feb 201011:37 amRNSDirector/PDMR Shareholding
5th Feb 20104:35 pmRNSPrice Monitoring Extension
29th Jan 20103:23 pmRNSTotal Voting Rights
28th Jan 201011:05 amRNSNotice of Results
28th Jan 20107:02 amRNSResearch Update
28th Jan 20107:00 amRNSResearch Update
20th Jan 20103:51 pmRNSEmployee Benefit Trust
5th Jan 20107:00 amRNSArk files for re-examination of Cerepro
22nd Dec 20094:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20094:35 pmRNSPrice Monitoring Extension
18th Dec 200911:56 amRNSEMEA recommendation on Cerepro
15th Dec 20092:29 pmRNSHolding(s) in Company
3rd Dec 20092:41 pmRNSBlocklisting Interim Review
3rd Dec 20092:35 pmRNSHolding(s) in Company
24th Nov 20094:04 pmRNSHolding(s) in Company
11th Nov 20097:00 amRNSInterim Management Statement
14th Oct 20097:00 amRNSResearch Update
2nd Oct 200911:04 amRNSHolding(s) in Company
30th Sep 200910:51 amRNSHolding(s) in Company
29th Sep 20094:32 pmRNSHolding(s) in Company
4th Sep 20097:00 amRNSResearch Update
1st Sep 200912:08 pmRNSDirector/PDMR Shareholding
26th Aug 20097:00 amRNSResearch Update
26th Aug 20097:00 amRNSHalf Yearly Report
13th Jul 20097:00 amRNSArk launches Kerraglove woundcare device
1st Jul 20097:00 amRNSRe Agreement
26th Jun 20092:15 pmRNSHolding(s) in Company
24th Jun 20097:00 amRNSManufacturing Update
17th Jun 20097:00 amRNSRe Agreement
3rd Jun 200911:47 amRNSBlocklisting Interim Review
21st May 20097:00 amRNSTrinam Phase III Study Enrols First Patient
18th May 20097:00 amRNSInterim Management Statement
15th May 20097:00 amRNSCerepro Named Patient Supply approved in Finland
13th May 20094:41 pmRNSSecond Price Monitoring Extn
13th May 20094:35 pmRNSPrice Monitoring Extension
12th May 20097:00 amRNSDirector/PDMR Shareholding
6th May 20094:40 pmRNSSecond Price Monitoring Extn
6th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20097:00 amRNSTrinam(R) Awarded Fast Track Status by FDA
30th Apr 20094:01 pmRNSTotal Voting Rights
30th Apr 200912:00 pmRNSPrestigious European Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.